Wednesday, May 22, 2013 Last update: 2:49 AM
Company Tech News as it Breaks
Trade Events
ARIAD Pharmaceuticals, Inc.
News articles for ARIAD Pharmaceuticals, Inc.:
Wednesday, May 15, 2013
- ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual MeetingARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig® (ponatinib) and AP26113, its investigational inhibitor of anaplastic lymphoma kinase ... read more
Monday, May 13, 2013
- ARIAD to Present at UBS Global Healthcare ConferenceARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the UBS Global Healthcare Conference being held in New York ... read more
Tuesday, May 7, 2013
- ARIAD Reports First Quarter 2013 Financial Results and Development ProgressARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter, including revenue from its first cancer medicine, Iclusig® ... read more
Monday, May 6, 2013
- ARIAD to Present at Bank of America Merrill Lynch Healthcare ConferenceARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Bank of America Merrill Lynch Healthcare Conference being held ... read more
Tuesday, April 23, 2013
- ARIAD to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, ... read more
Tuesday, April 9, 2013
- ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal TumorsARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of preclinical data on ponatinib (Iclusig™) at the American Association for Cancer Research ... read more
Monday, April 8, 2013
- ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung CancerARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of preclinical data on ponatinib (Iclusig™) , at the American Association for Cancer ... read more
Wednesday, April 3, 2013
- CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ETFirst graph, last sentence of release should read: The Company will take questions on the call. (sted The Company will not take questions on the call.) ... read moreARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ETARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will hold a conference call for the investment community tomorrow, April 4, 2013 ... read more
Tuesday, April 2, 2013
- ARIAD Announces Support of Patients with Resistant or Intolerant CML Through Its Donation to Chronic Disease FundARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it had made a donation to the Chronic Disease Fund (CDF) in support of ... read more
Wednesday, March 6, 2013
- ARIAD to Present at Barclays Global Healthcare ConferenceARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at Barclays Global Healthcare Conference being held in Miami. Harvey J. ... read more
Thursday, February 28, 2013
- ARIAD to Present at the Cowen and Company 33rd Annual Health Care ConferenceARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 33rd Annual Health Care Conference being ... read more
Wednesday, February 20, 2013
- ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership TeamARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jonathan E. Dickinson to the position of General Manager, ARIAD Pharmaceuticals (Europe), ... read more
Friday, February 8, 2013
- ARIAD to Present at the Leerink Swann Global Healthcare ConferenceARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Global Healthcare Conference being held in New ... read more
Tuesday, February 5, 2013
- ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012 Financial ResultsARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a live webcast of its quarterly conference call at 8:30 a.m. (ET) ... read more
Tuesday, January 29, 2013
- ARIAD Announces Completion of Public OfferingARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 ... read more
Thursday, January 24, 2013
- ARIAD Announces Pricing of Public Offering of Common StockARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of an underwritten public offering of 15,307,000 shares of its common stock, at a price to the public of ... read more
Wednesday, January 23, 2013
- ARIAD Announces Proposed Public Offering of Common StockARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering ... read more
Monday, January 7, 2013
- ARIAD and the U.K. National Cancer Research Institute to Collaborate on SPIRIT 3 Clinical StudyARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Newcastle University, U.K., on behalf of the U.K. National Cancer Research Institute (NCRI) CML Working Group, ... read more
Wednesday, January 2, 2013
- ARIAD to Present at the 31st Annual J.P. Morgan Healthcare ConferenceARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 31st Annual J.P. Morgan Healthcare Conference being held in ... read more